

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 20, 2024

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	-	Matthew Stanley, DO	X
Bill Ladwig, RPh	X	Brandi Tackett, PharmD	X
Mark List, MD	X	Deidra Van Gilder, PharmD, Chair	X
Kelley Oehlke, PharmD	X	Clarissa Barnes, MD, DSS Staff	X
Lenny Petrik, PharmD	X	Mike Jockheck, DSS Staff	X
Heather Preuss, MD	X	Taylor Koerner, DSS Staff	X

Administrative Business

Van Gilder called the meeting to order at 1:02 pm. Jockheck introduced new committee member Mark List, family physician at Avera in Sioux Falls. The minutes of the June meeting were presented. Ladwig made a motion to approve. Stanley seconded the motion. The motion to approve the minutes was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from April 1, 2024, to June 30, 2024. A total of 3,408 PAs were reviewed of which 126 requests (3.7%) were received via telephone, 102 requests (3%) were received via fax, 1,389 (40.7%) were reviewed electronically, and 1,789 requests (52.5%) were received via ePA. There was a 2.5% decrease in PAs received compared to the previous quarter. There was a 38% decrease in number of appeals.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2024, to June 30, 2024. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, incretin mimetics, and antineoplastic agents. These top 15 therapeutic classes comprise 22.02% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid constitute 8.32% of total claims.

Old Business

CGM review

Committee reviewed CGM utilization and compliance data. Van Gilder commented on the data showing some members had increased utilization of test strips with concurrent use of CGMs. Committee discussed implementing tighter glucose test strip limits for patients concurrently receiving CGMs. Mariham Fahim, Medical Outcomes Liaison from Abbott Diabetes Care, provided public comment. Ladwig stressed the importance of CGM data and asked about using a student to analyze A1C/outcomes data. Jockheck is open to working with Ladwig's or Van Gilder's students to review A1C and outcomes. Van Gilder asked to consider adding quantity limit for members using CGM. Ladwig discussed the appropriate number of strips for members using CGM. Van Gilder stated testing once per day is appropriate. Preuss made a motion to limit blood glucose test strips to #50 strips per month when using a CGM. Stanley second the

motion. The motion was approved unanimously. Jockheck asked for public comment on CGM compliance. Kimbra Brooks, Senior Regional Account Manager with Abbott Diabetes Care, provided input.

Veozah review

Veozah utilization and adherence data were presented for review. Committee will continue to monitor Veozah. Jeenal Choksi, Associate Director from Medical Value and Access at Astellas, provided public comment.

Zuruvuae review

Zuruvuae utilization and PA data were presented for review. Daphne Ni, Medical Liaison with Biogen, provided public comment. Stanley requested to monitor Zuzuvuae and repoll other state policies. Ladwig asked to continue monitoring. Lisa Gronneberg, Regional Account Director from Biogen, provided information from other states. Anne Carroll-Palmer, National Account Director with Sage, provided public comment. Crystal McAuley from the Policy Center from Maternal Mental Health provided public comment. The committee took no action.

Opioid Update

The committee reviewed 2Q2024 opioid outcomes compared to the previous quarter from the opioid initiatives. There was an increase in opioid utilization and utilizers during 2Q2024 with corresponding increase in total eligibility and utilizers. The committee also reviewed the average MME/day/utilizer graph.

New Business

GLP-1 review

Glucagon-like peptide-1 receptor (GLP-1) agonist multi-part review was presented to the committee. Committee was asked to consider step therapy on preferred drugs before non-preferred drug. Ladwig made a motion for a trial of one preferred drug for three months before allowing non-preferred product. Stanley seconded the motion. Van Gilder inquired if there was any public comment. There were none. The motion was approved unanimously.

Next the Committee reviewed the indication for major adverse cardiovascular event (MACE). Barnes provided insight on starting to expand access to these mediations starting with MACE. Shawn Hansen, Medical Account Director with Novo Nordisk, provided public comment. The committee discussed PA criteria. Tackett expressed concern with the suggested age range. Stanley made a motion to implement criteria A with coverage expanded to 18 years and older with the caveat to revisit the criteria again. Preuss seconded the motion. Motion passed unanimously.

ADHD review

This agenda item has been tabled until the next meeting.

Daybue

This agenda item has been tabled until the next meeting.

Adjournment

The next meeting is scheduled on December 13, 2024. The March meeting is scheduled for March 21, 2025. Preuss motioned to adjourn the meeting and Oehlke seconded the motion. The motion to adjourn the meeting was unanimous and the meeting adjourned at 3:03 pm CT.